EcoDrugPlus

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSLACG00000018713
Gene Symbol: CHRM4
4 Cross references
184 Possible Orthologues:

Cholinergic Receptor Muscarinic 5

Ensembl ID : ENSLACG00000009104
Gene Symbol: CHRM5
4 Cross references
263 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSLACG00000004838
Gene Symbol: CHRNA3
3 Cross references
198 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 4 Subunit

Ensembl ID : ENSLACG00000010383
Gene Symbol: CHRNA4
4 Cross references
204 Possible Orthologues:

Cholinergic Receptor Nicotinic Beta 2 Subunit

Ensembl ID : ENSLACG00000015217
Gene Symbol: CHRNB2
4 Cross references
197 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSLACG00000005760
Gene Symbol: CHRNA7A
4 Cross references
248 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor

Ensembl ID : ENSLACG00000009553
Gene Symbol: F2R
4 Cross references
327 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSLACG00000003127
Gene Symbol: F3
4 Cross references
243 Possible Orthologues:

Coagulation Factor Vii

Ensembl ID : ENSLACG00000001752
Gene Symbol: F7
4 Cross references
274 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSLACG00000001156
Gene Symbol: F10
2 Cross references
239 Possible Orthologues:

Coagulation Factor Xi

Ensembl ID : ENSLACG00000006566
Gene Symbol: F11
4 Cross references
216 Possible Orthologues:

Coiled-Coil Domain Containing 6

Ensembl ID : ENSLACG00000003679
Gene Symbol: CCDC6
4 Cross references
219 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).